COMBIVENT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COMBIVENT (COMBIVENT).
Combivent is a fixed-dose combination of ipratropium bromide, an anticholinergic agent that inhibits muscarinic receptors in bronchial smooth muscle leading to bronchodilation, and albuterol sulfate, a beta-2 adrenergic agonist that stimulates adenyl cyclase, increasing cyclic AMP, resulting in bronchodilation.
| Metabolism | Ipramatropium: partially metabolized by hydrolysis to inactive metabolites; Albuterol: primarily metabolized by sulfate conjugation via SULT1A3 and to a lesser extent by CYP450 enzymes (CYP3A4, CYP2D6) to 4'-O-sulfate. |
| Excretion | Ipratropium is primarily excreted renally as unchanged drug (approximately 50%) and metabolites (approximately 30%); fecal excretion accounts for about 10%. Albuterol undergoes hepatic metabolism to an inactive sulfate conjugate, with approximately 70-80% of a dose excreted renally as unchanged drug and metabolite; fecal excretion is minimal (<10%). |
| Half-life | Ipratropium: terminal elimination half-life of approximately 2 hours (range 1.5-4 hours) after inhalation. Albuterol: terminal elimination half-life of approximately 3.8-6 hours after inhalation; systemic half-life is clinically relevant for dosing frequency in asthma/COPD. |
| Protein binding | Ipratropium: approximately 0-9% bound to plasma proteins (predominantly albumin). Albuterol: approximately 10% bound to plasma proteins. |
| Volume of Distribution | Ipratropium: Vd approximately 2-4 L/kg (467 L for a 70 kg adult), indicating extensive tissue distribution. Albuterol: Vd approximately 1.5-2 L/kg (105-140 L for a 70 kg adult), consistent with moderate tissue distribution. |
| Bioavailability | Inhalation: Ipratropium absolute bioavailability of approximately 7-25% (due to pulmonary deposition and swallowed fraction). Albuterol inhaled bioavailability of approximately 10-20%. Oral bioavailability (swallowed) is low: ipratropium about 2-3%, albuterol about 30-50% but first-pass metabolism reduces systemic exposure. |
| Onset of Action | Inhalation: Ipratropium onset within 15 minutes, peak effect at 1-2 hours. Albuterol onset within 5-15 minutes, peak effect at 30-60 minutes. Combined product provides rapid bronchodilation. |
| Duration of Action | Inhalation: Ipratropium duration of 4-6 hours; albuterol duration of 4-6 hours. Clinically, Combivent provides bronchodilation for up to 5 hours in COPD patients. |
2 inhalations (ipratropium 18 mcg and albuterol 103 mcg per actuation) via oral inhalation 4 times daily; maximum 12 inhalations in 24 hours.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dose adjustment required for mild-to-moderate renal impairment (CrCl >30 mL/min). Caution in severe impairment (CrCl <30 mL/min) or dialysis; use reduced frequency or alternative therapy due to potential for systemic accumulation. |
| Liver impairment | No specific Child-Pugh based guidelines; caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance of albuterol, consider dose reduction or extended interval. |
| Pediatric use | Not recommended for children <6 years. For ≥6 years: 2 inhalations 4 times daily as needed, up to 12 inhalations/day. |
| Geriatric use | No specific dose adjustment; monitor for anticholinergic effects (e.g., dry mouth, urinary retention) and beta-adrenergic effects (e.g., tachycardia, tremor). Ensure proper inhaler technique; consider spacer use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COMBIVENT (COMBIVENT).
| Breastfeeding | Unknown if albuterol or ipratropium are excreted in human milk. M/P ratio not established. Caution advised; consider developmental and health benefits of breastfeeding along with mother's clinical need and potential adverse effects on nursing infant. |
| Teratogenic Risk | Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate showed teratogenicity (cleft palate) at high doses; ipratropium bromide showed no teratogenic effects. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: potential risk based on animal data. Second/third trimesters: albuterol may inhibit uterine contractions and cause maternal tachycardia, which may affect fetal heart rate; avoid near term due to possible neonatal hypoglycemia and hypokalemia. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to ipratropium, albuterol, or any component of the formulation","Hypersensitivity to atropine or its derivatives"]
| Precautions | ["Paradoxical bronchospasm","Immediate hypersensitivity reactions","Deterioration in renal function (ipratropium eliminated renally)","Cardiovascular effects: tachycardia, arrhythmias, hypertension (albuterol)","Hypokalemia (albuterol)","Increased intraocular pressure with nebulized ipratropium in glaucoma patients","Urinary retention in patients with prostatic hyperplasia or bladder neck obstruction"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, serum potassium, and signs of bronchospasm. Fetal monitoring: assess fetal heart rate and uterine activity; ultrasound for fetal growth if used long-term. Watch for maternal tachyarrhythmias, especially if used concomitantly with other sympathomimetics. |
| Fertility Effects | No specific data on Combivent effects on human fertility. Animal studies: albuterol at high doses impaired fertility in rats; ipratropium showed no adverse effects. Clinical relevance unknown. |